MindWalk Holdings (HYFT) Payables (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Payables of $3.0 million for Q2 2026, down 17.9% year-over-year from $3.7 million in Q2 2025, and up 26.87% quarter-over-quarter from $2.4 million in Q1 2026.
MindWalk Holdings (HYFT) Payables (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Payables for 7 consecutive years, with $3.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Payables fell 17.9% year-over-year to $3.0 million; the TTM figure through Apr 2026 stood at $3.0 million (down 17.9% YoY), while the FY2026 annual figure was $3.0 million, down 19.64% from the prior year.
- Payables improved to $3.0 million in Q2 2026 per HYFT's latest filing, from $2.4 million in the prior quarter.
- Across five years, Payables topped out at $3.9 million in Q4 2024 and bottomed at $1.7 million in Q3 2022.
- Historically, Payables has averaged $3.0 million across 5 years, with a median of $3.1 million in 2025.
- Annual changes were most pronounced in 2022 — Payables surged 57.41% — and 2025, when it plunged 37.24%.
- MindWalk Holdings' Payables stood at $3.6 million in 2022, then retreated by 16.31% to $3.0 million in 2023, then increased by 29.95% to $3.9 million in 2024, then slumped by 37.24% to $2.5 million in 2025, then increased by 23.19% to $3.0 million in 2026.
- Business Quant data shows HYFT's Payables at $3.0 million in Q2 2026, $2.4 million in Q1 2026, and $2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 3.05 Mn |
| Jan 31, 2026 | 2.40 Mn |
| Oct 31, 2025 | 2.47 Mn |
| Jul 31, 2025 | 2.38 Mn |
| Apr 30, 2025 | 3.71 Mn |
| Jan 31, 2025 | 3.09 Mn |
| Oct 31, 2024 | 3.94 Mn |
| Jul 31, 2024 | 3.52 Mn |
| Apr 30, 2024 | 3.22 Mn |
| Jan 31, 2024 | 3.55 Mn |
| Oct 31, 2023 | 3.03 Mn |
| Jul 31, 2023 | 2.66 Mn |
| Apr 30, 2023 | 2.50 Mn |
| Jan 31, 2023 | 3.19 Mn |
| Oct 31, 2022 | 3.62 Mn |
| Jul 31, 2022 | 1.75 Mn |
| Apr 30, 2022 | 3.76 Mn |
| Jan 31, 2022 | 2.60 Mn |
| Oct 31, 2021 | 2.86 Mn |
| Jul 31, 2021 | 2.42 Mn |